U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06889818) titled 'Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)' on March 14.
Brief Summary: The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to evaluate the impact of these new therapies and diagnostic techniques in clinical practice.
Study Start Date: Feb. 24
Study Type: OBS...